Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: entradatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $29.00 | Buy | ROTH MKM |
| 1/5/2024 | $22.00 | Outperform | Oppenheimer |
| 4/3/2023 | $25.00 | Buy | H.C. Wainwright |
| 11/24/2021 | Outperform | Evercore ISI Group | |
| 11/23/2021 | Outperform | Cowen & Co. | |
| 11/23/2021 | $29.00 | Neutral | Goldman Sachs |
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit
- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates. "In the first quarter, we successfully closed on our transformational collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1, the most prev
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt "Bernie" Zeiher to its Board of Directors, effective immediately. Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma. "Bernie is a dynamic life sciences leader and we look forward to having him join our Board of Directors," said Dipal Doshi, President and Chief Executive Officer of Entrada. "As the former Chief Medical Officer and President of Development at
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald previously served as Entrada's Vice President of Corporate Communications and Investor Relations. She remains a member of the Entrada executive team and will report to Dipal Doshi, Entrada's President and Chief Executive Officer. "Karla is a transformational leader who has already demonstrated her value as a membe
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates. "We are thrilled to begin 2025 with significant mome
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initi
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mu
BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. "Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical industries," said John Marotta, President and CEO of Azenta. "His experience in strategy, operational and commercial growth, and
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET). A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.
– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clinical trials for both ENTR-601-44 and ENTR-601-45 in Q4 2024 – – Vertex announced the completion of the single ascending dose (SAD) and the initiation of the multiple ascending dose (MAD) portions of global Phase 1/2 clinical trial for partnered program VX-670 in people with DM1 – – Cash runway expected into 2027 with $449 million in cash, cash equivalents and marketable securities as of September 30, 2024 – BOSTON, Nov. 05, 2024 (GLOBE NEWS
– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented for the first time, showing exon skipping and dystrophin production for ENTR-601-45, supports the planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 clinical trial – BOSTON, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets lo
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately. "Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company's diverse pipeline of proprietary intracellular therapeutics," said Dipal Doshi, Chief Ex
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,
- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced the recipients of its second annua
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00
Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00
H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00
Evercore ISI Group initiated coverage of Entrada Therapeutics with a rating of Outperform
Cowen & Co. initiated coverage of Entrada Therapeutics with a rating of Outperform
Goldman Sachs initiated coverage of Entrada Therapeutics with a rating of Neutral and set a new price target of $29.00
S-8 - Entrada Therapeutics, Inc. (0001689375) (Filer)
10-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
SCHEDULE 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SCHEDULE 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)